Abnormally large giant-nucleus cells that survive iron-induced oxidative stress form the foundation of early-stage cancer, according to a Japanese research team at the Nagoya University Graduate School of Medicine whose findings were published in the journal Redox Biology. While excess iron damages cells and increases cancer risk, a subset of cells survives the damage by developing resistance to ferroptosis, an iron-dependent form of cell death. These distinct giant-nucleus cells could serve as early indicators of cancer because they are easy to identify under a microscope.
Mapping Iron-Induced Damage in Rodent Models
To explore the mechanism by which surviving cells evolve toward a cancerous condition, Nagoya University professor emeritus and lead researcher Shinya Toyokuni, along with Assistant Professor Yingyi Kong and fellow researchers, performed tests utilizing wild-type rats alongside counterparts possessing a single mutated BRCA1 gene. According to the research team, scientists have spotted cells with abnormally large nuclei during the early phases of oxidative-stress-driven cancer since the 1980s, but their exact role remained unclear.
Researchers injected ferric nitrilotriacetate, a carcinogenic iron compound, into rats to induce kidney damage. The team collected kidney tissue samples before the injection and one and three weeks afterward. By utilizing spatial transcriptomics, the researchers mapped gene activity in individual cells while preserving the tissue’s original structure, then paired this data with computational analyses to quantify the size, shape, and density of cell nuclei.
How Surviving Cells Acquire Precancerous Traits
Within one week of the iron administration, giant-nucleus cells emerged with increased expression of cancer-related genes such as Myc and Met. These cells also developed resistance to ferroptosis, an iron-dependent form of cell death. The experiments revealed that BRCA1-mutant rats developed giant-nucleus cells with distinct biological profiles from wild-type rats, indicating that BRCA1 deficiency impairs DNA repair, allowing more precancerous giant-nucleus cells to survive.
Furthermore, morphologically normal cells near giant-nucleus cells exhibited gene expression changes that may promote their survival. This suggests that large nuclei in kidney cells could signal early cancer development in surrounding tissue. Kidneys from BRCA1-mutant rats also displayed a substantial increase in stromal cells (non-cancerous supportive cells, including immune and connective tissue elements) around damaged regions, pointing to a more pronounced alteration of the local tissue environment in these cases.
Did you know? By analyzing gene activity and nuclear morphology, researchers classified giant-nucleus cells into six types, with another type—more common in BRCA1-mutant kidneys—showing increased cancer-related gene activity and elongated nuclei, indicating a potential precancerous state.
Linking Animal Models to Human Patient Outcomes
To test whether these animal models translate to human disease, the research team analyzed data from the TCGA-KIRC, a large public database of kidney cancer patients. Shorter survival times characterized patients whose tumors shared gene patterns with cancer-prone giant-nucleus cells, whereas individuals possessing patterns typical of healthier giant-nucleus cells experienced more favorable prognoses. Examining breast tissue samples in a compact pilot investigation, the scientists noted comparable nuclear abnormalities in seven people with hereditary BRCA1 mutations relative to 15 control subjects lacking the mutation.
“Using spatial transcriptomics, we categorized giant-nucleus cells into six types for the first time and detailed their cancer-linked traits,” Toyokuni said. “By comparing these features with human data, we found that these cell types could help predict patient outcomes.” Extended investigations will prove vital to establish the progression pathway of giant-nucleus cells into tumors, evaluate if blocking mitochondrial shifts or ferroptosis resistance stops cancer development, and assess whether nuclear morphology and gene signatures can improve kidney cancer diagnosis or prediction across broader patient populations.
Frequently Asked Questions
What are giant-nucleus cells?
Giant-nucleus cells are abnormally large cells that emerge when a subset of cells survives iron-induced oxidative stress and cell damage.
How do these cells relate to cancer?
According to Nagoya University researchers, these surviving cells show increased expression of cancer-related genes like Myc and Met, forming the foundation of early-stage cancer.
Can these cells be used to predict patient outcomes?
Yes. Researchers found that patient tumors sharing gene patterns with cancer-prone giant-nucleus cells had shorter survival times.
What is ferroptosis?
Ferroptosis is an iron-dependent form of cell death that giant-nucleus cells develop resistance against.
Explore More: Dive deeper into our archives for the latest updates on oncology research, or subscribe to our newsletter for weekly updates on breakthrough scientific discoveries.
Keep reading